NEW YORK (GenomeWeb) – Pacific Biosciences has received a $10 million payment from Roche for hitting a development milestone that is part of the commercialization and license agreement the companies struck in 2013, according to a PacBio filing with the US Securities and Exchange Commission.

PacBio didn't disclose what development milestone had been met, but noted that it may receive up to $30 million in the future for reaching additional development milestones. It said that the payment will be recorded as contractual revenue in its third quarter financial statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.